Two ongoing randomized trials are examining the efficacy of SGLT2 inhibitors in patients with HFpEF: Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER; NCT03619213) and Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved; NCT03057951). This evidence concerns the gene SLC5A2 and heart failure.